Ai Huang1, Yong Xiao2, Chunfen Peng1, Tao Liu1, Zhenyu Lin1, Qin Yang1, Tao Zhang1, Jun Liu3, Hong Ma4. 1. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China. 2. Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China. 3. School of Electrical and Electronic Engineering, Nanyang Technological University, 639798, Singapore, Singapore. 4. Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China. wudajianzhu2004@163.com.
Abstract
PURPOSE: Considering the effects of P53 binding protein 1 (53BP1) expression and T lymphocyte infiltration density on tumor radiosensitivity, we investigated the relation of 53BP1 expression and immunoscore based on T lymphocyte infiltration density with the efficacy of neoadjuvant chemoradiotherapy (CRT) for rectal cancer. METHODS: Fifty-five patients with rectal cancer receiving neoadjuvant CRT followed by surgery were enrolled. The 53BP1 expression level and the density of CD3+, CD8+, and CD45RO+ T lymphocytes in the tumor tissues were examined by immunohistochemistry, and the relation of these findings to the rates of tumor regression, disease-free survival (DFS), and overall survival (OS) was analyzed. RESULTS: The levels of 53BP1 and the CD3/CD8 immunoscore were closely correlated with the response to CRT (p < 0.05), with an area under the receiver operating characteristic curve for CRT efficacy prediction of 0.626 and 0.717, respectively. Further survival analysis revealed that high 53BP1 expression effectively prolonged 2‑year DFS compared with low 53BP1 expression (87.5% [95%CI 77.3-97.7] vs. 53.3% [95%CI 28.1-78.6]; p < 0.05), while the effect of immunoscore on survival was restricted by the expression status of 53BP1. Cox multivariate analysis confirmed 53BP1 as an independent prognostic factor in DFS. CONCLUSION: The pretreatment levels of 53BP1 and the immunoscore based on CD3+/CD8+ T cell infiltration density in tumor tissues are effective predictors for the CRT response, and 53BP1 has a more pronounced impact on prognosis.
PURPOSE: Considering the effects of P53 binding protein 1 (53BP1) expression and T lymphocyte infiltration density on tumor radiosensitivity, we investigated the relation of 53BP1 expression and immunoscore based on T lymphocyte infiltration density with the efficacy of neoadjuvant chemoradiotherapy (CRT) for rectal cancer. METHODS: Fifty-five patients with rectal cancer receiving neoadjuvant CRT followed by surgery were enrolled. The 53BP1 expression level and the density of CD3+, CD8+, and CD45RO+ T lymphocytes in the tumor tissues were examined by immunohistochemistry, and the relation of these findings to the rates of tumor regression, disease-free survival (DFS), and overall survival (OS) was analyzed. RESULTS: The levels of 53BP1 and the CD3/CD8 immunoscore were closely correlated with the response to CRT (p < 0.05), with an area under the receiver operating characteristic curve for CRT efficacy prediction of 0.626 and 0.717, respectively. Further survival analysis revealed that high 53BP1 expression effectively prolonged 2‑year DFS compared with low 53BP1 expression (87.5% [95%CI 77.3-97.7] vs. 53.3% [95%CI 28.1-78.6]; p < 0.05), while the effect of immunoscore on survival was restricted by the expression status of 53BP1. Cox multivariate analysis confirmed 53BP1 as an independent prognostic factor in DFS. CONCLUSION: The pretreatment levels of 53BP1 and the immunoscore based on CD3+/CD8+ T cell infiltration density in tumor tissues are effective predictors for the CRT response, and 53BP1 has a more pronounced impact on prognosis.
Entities:
Keywords:
Immune scores; P53 binding protein 1; Radiation sensitivity; Rectal cancer; Tumor inflitrating T cells
Authors: Ulrika A Hänninen; Erkki-Ville Wirta; Riku Katainen; Tomas Tanskanen; Jiri Hamberg; Minna Taipale; Jan Böhm; Laura Renkonen-Sinisalo; Anna Lepistö; Linda M Forsström; Esa Pitkänen; Kimmo Palin; Toni T Seppälä; Netta Mäkinen; Jukka-Pekka Mecklin; Lauri A Aaltonen Journal: Br J Cancer Date: 2019-03-21 Impact factor: 7.640
Authors: Ana Teresa G Fernandes; Maria Odete O Carvalho; Elyzabeth Avvad-Portari; Natália P Rocha; Fabio Russomano; Eric Henrique Roma; Maria da Gloria Bonecini-Almeida Journal: Sci Rep Date: 2021-04-22 Impact factor: 4.379
Authors: Barbara Schuster; Markus Hecht; Manfred Schmidt; Marlen Haderlein; Tina Jost; Maike Büttner-Herold; Klaus Weber; Axel Denz; Robert Grützmann; Arndt Hartmann; Hans Geinitz; Rainer Fietkau; Luitpold V Distel Journal: Cancers (Basel) Date: 2021-12-29 Impact factor: 6.639
Authors: Thorsten Derlin; Natalia Bogdanova; Fiona Ohlendorf; Dhanya Ramachandran; Rudolf A Werner; Tobias L Ross; Hans Christiansen; Frank M Bengel; Christoph Henkenberens Journal: Cancers (Basel) Date: 2021-03-25 Impact factor: 6.639